Evercore ISI Trims OraSure Technologies (NASDAQ:OSUR) Target Price to $4.50

OraSure Technologies (NASDAQ:OSUR) had its price objective decreased by Evercore ISI from $5.50 to $4.50 in a research report sent to investors on Tuesday morning, Benzinga reports. Evercore ISI currently has an in-line rating on the medical instruments supplier’s stock.

Other research analysts also recently issued research reports about the company. StockNews.com downgraded OraSure Technologies from a buy rating to a hold rating in a report on Thursday, May 9th. JPMorgan Chase & Co. cut their target price on OraSure Technologies from $7.00 to $6.00 and set a neutral rating on the stock in a research report on Monday, May 13th. Three analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, OraSure Technologies currently has a consensus rating of Hold and a consensus price target of $6.13.

OraSure Technologies Stock Down 4.4 %

Shares of NASDAQ:OSUR opened at $4.08 on Tuesday. The company has a market capitalization of $301.76 million, a price-to-earnings ratio of 13.60 and a beta of 0.09. The company has a 50 day moving average of $4.82 and a two-hundred day moving average of $6.28. OraSure Technologies has a 52-week low of $4.07 and a 52-week high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, May 8th. The medical instruments supplier reported $0.04 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.04. OraSure Technologies had a net margin of 7.50% and a return on equity of 7.68%. The business had revenue of $54.10 million during the quarter, compared to analyst estimates of $52.27 million. During the same period last year, the business earned $0.37 EPS. The business’s revenue was down 65.1% on a year-over-year basis. On average, equities analysts anticipate that OraSure Technologies will post -0.08 earnings per share for the current year.

Institutional Investors Weigh In On OraSure Technologies

A number of institutional investors have recently made changes to their positions in OSUR. Trexquant Investment LP grew its holdings in shares of OraSure Technologies by 3.3% during the third quarter. Trexquant Investment LP now owns 64,644 shares of the medical instruments supplier’s stock valued at $383,000 after purchasing an additional 2,049 shares during the last quarter. Diversified Trust Co grew its stake in OraSure Technologies by 17.7% during the 4th quarter. Diversified Trust Co now owns 16,031 shares of the medical instruments supplier’s stock worth $131,000 after buying an additional 2,406 shares during the last quarter. Tocqueville Asset Management L.P. grew its position in shares of OraSure Technologies by 20.0% during the first quarter. Tocqueville Asset Management L.P. now owns 15,089 shares of the medical instruments supplier’s stock worth $93,000 after acquiring an additional 2,512 shares during the last quarter. AJOVista LLC bought a new position in OraSure Technologies in the 4th quarter worth about $39,000. Finally, Lazard Asset Management LLC increased its position in OraSure Technologies by 12.9% in the 1st quarter. Lazard Asset Management LLC now owns 56,908 shares of the medical instruments supplier’s stock valued at $349,000 after acquiring an additional 6,500 shares during the period. 93.50% of the stock is currently owned by institutional investors.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.